# A Single Dose, Cross-over Bioequivence Study Comparing Galantamine IR (Immediate Release) Table and Galantmine OS (Oral Solution) in Healthy Volunteers

> **NCT00645554** · PHASE1 · COMPLETED · sponsor: **Xian-Janssen Pharmaceutical Ltd.** · enrollment: 2 (actual)

## Conditions studied

- Pharmacokinetics

## Interventions

- **DRUG:** Galantamine oral solution

## Key facts

- **NCT ID:** NCT00645554
- **Lead sponsor:** Xian-Janssen Pharmaceutical Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2004-09
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2011-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00645554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00645554, "A Single Dose, Cross-over Bioequivence Study Comparing Galantamine IR (Immediate Release) Table and Galantmine OS (Oral Solution) in Healthy Volunteers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00645554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*